Clinical Trials in Tennessee

Showing 13201-13220 of 20,239 trials

Hatha Yoga in Breast Cancer Survivors

NCT02923037

This pilot clinical trial studies Hatha yoga in reducing physical and emotional problems in breast cancer survivors with stage II-III lymphedema. Yoga practices may benefit breast cancer survivors with lymphedema as they directly support lymph transport (postures, breathing, relaxation) and emotional well-being (relaxation, meditation).

Breast CarcinomaLymphedema

Vanderbilt-Ingram Cancer Center27 participantsStarted Sep 2016

Nashville, Tennessee, United States

COMPLETEDPhase 1/229 miles

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

NCT02048488

TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2. The tropomyosin-related kinases TRKA, TRKB, and TRKC This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.

Solid TumorsLymphomas

Tesaro, Inc.72 participantsStarted Oct 2012

Goodyear, Arizona, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +12 more locations

COMPLETEDPhase 129 miles

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

NCT03048344

Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses. Subjects with the following advanced hematological disorders and no available therapies, and who satisfy all inclusion/exclusion criteria will be enrolled. The purpose is to identify the recommended dose of oral ORH-2014 in subjects with advanced hematological disorders. Part 2 will be an expansion phase conducted as a single-arm, open-label study to further evaluate the safety and tolerability of ORH-2014 at the maximum tolerated dose (MTD) or recommended dose determined from Part 1 in the fasted state. Subjects with the same disease types as in Part 1 will be enrolled. All subjects will receive oral ORH-2014, in the fasted state, at the recommended dose for an initial period of up to 12 weeks. The purpose is to evaluate the safety and tolerability of oral ORH-2014 in a population of subjects with advanced hematological disorders when administered at the recommended dose.

Advanced Hematological Disorders

Orsenix LLC12 participantsStarted Dec 2016

New York, New York, United States • New York, New York, United States • Nashville, Tennessee, United States +1 more locations

Hatha Yoga in Breast Cancer Survivors

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Find Trials by Condition in Tennessee

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Observational Study of Surgical Treatment of Necrotizing Enterocolotis

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Whole-Body Cooling for Birth Asphyxia in Term Infants

Early Diagnosis of Candidiasis in Premature Infants

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies

Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

Hemodynamic Assessment in Acute Decompensated Heart Failure